Forefront Analytics, LLC
- SEC CIK
- 0001696802
- Latest filing
- Aug 12, 2026
Holdings changes from Q2 2022 to Q3 2022
Long positions only; new, added, reduced and sold out are based on share counts. Pick any two quarters this institution filed.
- New
- 4
- Est. +$701.0K
- Added
- 27
- Est. +$868.6K
- Reduced
- 26
- Est. −$3.01M
- Sold out
- 4
- Est. −$558.0K
Portfolio value went from $206.4M to $187.8M (−$18.7M (−9.0%)); positions from 66 to 66 (0).
All Q3 2022 holdingsAll Q2 2022 holdings
In the shares, value and % of portfolio columns, the top figure is Q3 2022 and the gray one below is Q2 2022. For stocks that split between the two quarters, Q2 2022 shares are converted at the split ratio before comparing.
| Security | Action | Shares | Share change | Value | Est. bought or sold | % of portfolio | Weight change (pp) |
|---|---|---|---|---|---|---|---|
| Achilles Therapeutics PLC00449L102 | New– | 32,2000 | +32,200 | $72.0K$0 | +$72.0K | <0.1%0.0% | +0.04 |
| THRXTheseus Pharmaceuticals, Inc. | NewHistory | 13,0650 | +13,065 | $74.0K$0 | +$74.0K | <0.1%0.0% | +0.04 |
| REGNRegeneron Pharmaceuticals, Inc. | NewHistory | 3150 | +315 | $216.0K$0 | +$216.0K | 0.1%0.0% | +0.12 |
| UNHUnitedHealth Group Inc | NewHistory | 6620 | +662 | $339.0K$0 | +$339.0K | 0.2%0.0% | +0.18 |
Estimated amounts multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares): new positions use this quarter's value and sold-out positions last quarter's; positions reported only as principal (PRN) cannot be estimated. 13F shows only quarter-end holdings, not when trades happened or at what price.